Danaher Corporation $DHR Shares Purchased by Evelyn Partners Investment Management Europe Ltd

Evelyn Partners Investment Management Europe Ltd grew its stake in shares of Danaher Corporation (NYSE:DHR) by 217.0% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,192 shares of the conglomerate’s stock after buying an additional 2,185 shares during the period. Danaher accounts for 0.7% of Evelyn Partners Investment Management Europe Ltd’s investment portfolio, making the stock its 28th biggest position. Evelyn Partners Investment Management Europe Ltd’s holdings in Danaher were worth $630,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in DHR. Pacific Capital Partners Ltd acquired a new position in shares of Danaher in the first quarter valued at approximately $7,175,000. AE Wealth Management LLC grew its stake in Danaher by 1.9% in the 1st quarter. AE Wealth Management LLC now owns 12,406 shares of the conglomerate’s stock worth $2,543,000 after acquiring an additional 232 shares during the period. Pinnacle Associates Ltd. raised its holdings in Danaher by 5.3% in the 1st quarter. Pinnacle Associates Ltd. now owns 26,457 shares of the conglomerate’s stock valued at $5,424,000 after acquiring an additional 1,323 shares during the last quarter. Journey Strategic Wealth LLC lifted its stake in shares of Danaher by 41.7% during the 1st quarter. Journey Strategic Wealth LLC now owns 4,199 shares of the conglomerate’s stock worth $861,000 after purchasing an additional 1,236 shares during the period. Finally, Avantax Advisory Services Inc. boosted its holdings in shares of Danaher by 14.5% during the first quarter. Avantax Advisory Services Inc. now owns 43,641 shares of the conglomerate’s stock worth $8,946,000 after purchasing an additional 5,533 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

DHR has been the subject of several analyst reports. TD Cowen upped their target price on Danaher from $250.00 to $260.00 and gave the company a “buy” rating in a research note on Wednesday, October 22nd. Barclays upped their price objective on shares of Danaher from $225.00 to $250.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Wells Fargo & Company reissued a “positive” rating on shares of Danaher in a research report on Thursday, October 23rd. Bank of America lowered their target price on shares of Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a report on Monday, September 22nd. Finally, Deutsche Bank Aktiengesellschaft increased their price target on shares of Danaher from $235.00 to $250.00 and gave the stock a “buy” rating in a research note on Wednesday, October 22nd. Eighteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $243.39.

Insiders Place Their Bets

In related news, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the sale, the senior vice president directly owned 14,553 shares in the company, valued at approximately $3,190,454.19. This trade represents a 59.94% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Teri List sold 3,298 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total value of $746,997.00. Following the transaction, the director directly owned 20,762 shares in the company, valued at $4,702,593. This trade represents a 13.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 30,248 shares of company stock worth $6,609,663 over the last quarter. 11.10% of the stock is owned by corporate insiders.

Danaher Trading Up 2.3%

NYSE DHR opened at $227.34 on Friday. The firm has a market capitalization of $160.58 billion, a price-to-earnings ratio of 46.88, a PEG ratio of 3.28 and a beta of 0.81. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. Danaher Corporation has a one year low of $171.00 and a one year high of $258.23. The company’s 50 day moving average price is $208.58 and its 200 day moving average price is $201.97.

Danaher (NYSE:DHR) last released its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company had revenue of $6.05 billion during the quarter, compared to analyst estimates of $6 billion. During the same quarter in the prior year, the business earned $1.71 earnings per share. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. On average, sell-side analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were given a $0.32 dividend. The ex-dividend date of this dividend was Friday, September 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s dividend payout ratio (DPR) is 26.39%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.